Clinuvel Pharmaceuticals Ltd ADR(CUVL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 10.94 | EPS (ttm) | 0.46 | Insider Own | - | Shs Outstand | 50.4M | Perf Week | -0.59% |
| Market Cap | 0.25B | Forward P/E | 10.22 | EPS next Y | 3.44% | Insider Trans | - | Shs Float | 37.8M | Perf Month | -13.13% |
| Enterprise Value | 0.08B | PEG | 0.9 | EPS next Q | 0.18 | Inst Own | 0.01% | Short Float | 0.03% | Perf Quarter | -27.63% |
| Income | 0.02B | P/S | 3.95 | EPS this Y | -0.97% | Inst Trans | 0.1% | Short Ratio | 0.93 | Perf Half Y | -23.15% |
| Sales | 0.06B | P/B | 1.34 | EPS next 5Y | 11.32% | ROA | 12.16% | Short Interest | 0.01M | Perf YTD | -40.68% |
| Book/sh | 3.75 | P/C | 1.45 | EPS past 3/5Y | 3.32% 4.25% | ROE | 13.45% | 52W High | -43.61% ($8.92) | Perf Year | -33.38% |
| Cash/sh | 3.46 | P/FCF | 10.24 | Sales past 3/5Y | 6.54% 12.24% | ROIC | 12.27% | 52W Low | 2.44% ($4.91) | Perf 3Y | -49.77% |
| Dividend Est. | $0.04 (0.76%) | EV/EBITDA | 2.82 | EPS Y/Y TTM | -0.47% | Gross Margin | 82.84% | Volatility(W/M) | 3.61% 2.68% | Perf 5Y | -82.81% |
| Dividend TTM | 0.04 | EV/Sales | 1.25 | Sales Y/Y TTM | 5.04% | Oper. Margin | 43.47% | ATR (14) | 0.24 | Perf 10Y | -5% |
| Dividend Ex-Date | 2026/9/8 | Quick Ratio | 14.45 | EPS Q/Q | 16.8% | Profit Margin | 36.28% | RSI (14) | 32.56 | Recom | 2.14 |
| Dividend Gr. 3/5Y | - 24.57% | Current Ratio | 14.81 | Sales Q/Q | 6.5% | SMA20 | -8.96% ($5.53) | Beta | 0.91 | Target Price | $11.8 |
| Payout | 6.19% | Debt/Eq | 0.01 | Earnings | 2026/8/26 | SMA50 | -16.91% ($6.05) | Rel Volume | 1.84 | Prev Close | $5.12 |
| Employees | - | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | 0.91% -1.62% | SMA200 | -28.11% ($7) | Avg Volume(3M) | 0.01M | Price | $5.03 |
| IPO | 2004/7/2 | Option/Short | No/Yes | Trades | 522 | Volume | 23,849 | Change | -1.76% |
🧬 An Australia-based specialty pharmaceutical company that develops and sells treatments for rare light-related diseases. Its flagship product is a systemic photoprotective drug designed to prevent phototoxicity in adult patients with erythropoietic protoporphyria, and it has received commercial distribution approvals in Europe, the United States, Israel, and Australia, where it generates revenue.
Over the past 1 year, on the lower side
44% below its 1-year high.
Traded more than usual. That is 184% of its average volume.
CUVL makes money exceptionally well
Of every $100 in sales, $43.47 is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -1.0% this year.
Tap to view numbers
Within its industry, it looks cheap
For a company expected to earn $100 next year, you would pay $1,022. Peers typically go for $1,561.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -82.8%. The S&P 500 did +69% over the same period.
Tap to view numbers
The dividend is on the small side
Pays 0.76% annually in dividends.
Tap to view numbers
Institutions barely hold it
Institutions hold 0.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
GWX State Street SPDR S&P International Small Cap ETF <0.01% 
ISCF iShares International Small-Cap Equity Factor ETF <0.01% 
AVDS Avantis International Small Cap Equity ETF <0.01% 
DFIS Dimensional International Small Cap ETF <0.01% 
KAIT KraneShares Asia AI Technology ETF <0.01% It ranks #276 of 594 in the industry
Based on market cap of $254M.
ABEO#274 Abeona Therapeutics Inc $256M PER - 
ACIU#275 AC Immune SA $254M PER - CUVL#276 Clinuvel Pharmaceuticals Ltd ADR $254M PER 10.9 
RCKT#277 Rocket Pharmaceuticals Inc $254M PER - 
FATE#278 Fate Therapeutics Inc $250M PER - 
FAQ
What kind of company is CUVL?
CUVL belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CUVL?
The market cap of CUVL is approximately $254M, ranking 3,817 within its sector.
Does CUVL pay dividends?
CUVL has a dividend yield of approximately 0.76%, with an annual dividend of $0.04.
What is the P/E ratio of CUVL?
CUVL has a P/E ratio of approximately 10.9x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for CUVL?
CUVL has recorded a 52-week high of $8.92 and a low of $4.91.
